3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Barrett Esophagus
6
Stomach Neoplasms
4
Gastritis
3
Zollinger-Ellison Syndrome
2
Stomach Ulcer
2
Peptic Ulcer
2
Esophageal Neoplasms
2
Dyspepsia
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Precancerous Conditions
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma
1
Hot Flashes
1
Hemorrhage
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastroesophageal Reflux
1
Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
1
Esophagitis, Peptic
1
Colonic Neoplasms
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Imatinib Mesylate
41
Sunitinib
17
nilotinib
12
regorafenib
10
ripretinib
6
avapritinib
6
Leucovorin
3
Ipilimumab
3
Gemcitabine
3
Dasatinib
3
CTLA-4 Antigen
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
Paclitaxel
2
Oxaliplatin
2
Midazolam
2
Irinotecan
2
Fluorouracil
2
Floxuridine
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
Biopsy, Fine-Needle
2
Bevacizumab
2
vatalanib
1
umbralisib
1
trametinib
1
tinostamustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Stromal Tumors
×
Esomeprazole
×
Clear all
NCT02800330
2018-08-02
REGORA
Erasmus Medical Center
Phase 4
Completed
31 enrolled